ScholarLens Back to search
2023•Unpublished venueOpen access

Figure S1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Stephanie Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne M. Noonan, Paige Griffith, Marina Baretti, Won Jin Ho, Ihab R. Kamel, Mark Yarchoan, David Hsiehchen

Open full text 0 citations

Abstract

Figure S1. Survival Characteristics by Response

Open-access reader

About this research paper

What this paper is about

Figure S1. Survival Characteristics by Response

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Figure S1. Survival Characteristics by Response

Key concepts: Nivolumab, Ipilimumab, Hepatocellular carcinoma, PD-L1, Medicine, Salvage therapy, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Figure S1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma — Research Paper | ScholarLens